{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:23:12Z","timestamp":1782512592768,"version":"3.54.5"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Medical Microbiology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ijmmb.2022.11.005","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T07:29:53Z","timestamp":1670570993000},"page":"71-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["India-discovered levonadifloxacin & alalevonadifloxacin: A review on susceptibility testing methods, CLSI quality control and breakpoints along with a brief account of their emerging therapeutic profile as a novel standard-of-care"],"prefix":"10.1016","volume":"41","author":[{"given":"Balaji","family":"Veeraraghavan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamuna Devi","family":"Bakthavatchalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abi","family":"Manesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binesh","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramanian","family":"Swaminathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul","family":"Ansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Subbareddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Rangappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2436-4880","authenticated-orcid":false,"given":"Anirban Hom","family":"Choudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasant","family":"Nagvekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yatin","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boppe","family":"Appalaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata","family":"Baveja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrikala","family":"Baliga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchitra","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu","family":"Bhardwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9470-126X","authenticated-orcid":false,"given":"Vaishali","family":"Kongre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gogi Suresh","family":"Dattatraya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binita","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.N.","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyadarshini","family":"Shanmugam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Iravane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhi Ranjan","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purabi","family":"Barman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimpi","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenakshi","family":"Hariharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra","family":"Surpam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Pratap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilip","family":"Turbadkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shripad","family":"Taklikar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijmmb.2022.11.005_bib1","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/jac\/dkp377","article-title":"Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer?","volume":"65","author":"Nguyen","year":"2009","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib3","doi-asserted-by":"crossref","first-page":"478","DOI":"10.4103\/ijmm.IJMM_20_34","article-title":"A\u00a0comparative assessment of clinical, pharmacological and antimicrobial profile of novel anti-methicillin-resistant Staphylococcus aureus agent levonadifloxacin: therapeutic role in nosocomial and community infections","volume":"37","author":"Bakthavatchalam","year":"2019","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib4","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1128\/JCM.01588-06","article-title":"Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp","volume":"45","author":"Jones","year":"2007","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib5","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1128\/JCM.00665-06","article-title":"Multicenter evaluation of the Etest and disk diffusion methods for differentiating daptomycin-susceptible from non-daptomycin-susceptible Staphylococcus aureus isolates","volume":"44","author":"Jevitt","year":"2006","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib6","first-page":"30","article-title":"Efficacy and safety of a novel broad-spectrum anti-MRSA agent levonadifloxacin compared with linezolid for acute bacterial skin and skin structure infections: a Phase 3, openlabel, randomized study","volume":"68","author":"Bhatia","year":"2020","journal-title":"J\u00a0Assoc Phys India"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib7","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1021\/jm050035f","article-title":"A\u00a0chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus","volume":"48","author":"de Souza","year":"2005","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib8","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1021\/jm050035f","article-title":"A\u00a0chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus","volume":"48","author":"de Souza","year":"2005","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib9","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1128\/AAC.00641-06","article-title":"The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase","volume":"50","author":"Bhagwat","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib10","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.2147\/DDDT.S229882","article-title":"Levonadifloxacin, a novel broad-spectrum anti-MRSA benzoquinolizine quinolone agent: review of current evidence","volume":"13","author":"Bhagwat","year":"2019","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00909-19","article-title":"In vivo pharmacokinetic\/pharmacodynamic targets of levonadifloxacin against Staphylococcus aureus in a neutropenic murine lung infection model","volume":"63","author":"Bhagwat","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128432","article-title":"Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection","volume":"54","author":"Bhawsar","year":"2021","journal-title":"Bioorg Med Chem Lett"},{"issue":"Suppl 2","key":"10.1016\/j.ijmmb.2022.11.005_bib13","first-page":"ii75","article-title":"Safety and tolerability of ertapenem","volume":"53","author":"Teppler","year":"2004","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib14","series-title":"Development of in vitro susceptibility testing Criteria and quality control parameters","year":"2012"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.5354","article-title":"Ensuring robustness in the quality of antibiotic susceptibility test discs for four novel antibiotics","volume":"36","author":"Ahirrao","year":"2022","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib16","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1128\/CMR.00047-06","article-title":"Setting and revising antibacterial susceptibility breakpoints","volume":"20","author":"Turnidge","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib17","doi-asserted-by":"crossref","first-page":"E37","DOI":"10.1111\/j.1469-0691.2011.03752.x","article-title":"The role of pharmacokinetics\/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach","volume":"18","author":"Mouton","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib18","series-title":"Pharmacokinetic-pharmacodynamic (PK\/PD) target attainment (TA) analyses to support WCK 771 (INN: levonadifloxacin) clinical dose selection","author":"Bhagwat","year":"2019"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkz089","article-title":"Pharmacokinetic\/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia","volume":"74","author":"Bhavnani","year":"2019","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib20","doi-asserted-by":"crossref","first-page":"478","DOI":"10.4103\/ijmm.IJMM_20_34","article-title":"A\u00a0comparative assessment of clinical, pharmacological and antimicrobial profile of novel anti-methicillin-resistant Staphylococcus aureus agent levonadifloxacin: therapeutic role in nosocomial and community infections","volume":"37","author":"Bakthavatchalam","year":"2019","journal-title":"Indian J Med Microbiol"},{"issue":"3","key":"10.1016\/j.ijmmb.2022.11.005_bib21","article-title":"Intrapulmonary pharmacokinetics of levonadifloxacin following oral administration of alalevonadifloxacin to healthy adult subjects","volume":"62","author":"Rodvold","year":"2018","journal-title":"AAC (Antimicrob Agents Chemother)"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4103\/ijabmr.ijabmr_602_21","article-title":"Prescription-Event monitoring study on safety and efficacy of levonadifloxacin (oral and I.V.) in management of bacterial infections: findings of real-world observational study","volume":"12","author":"Mehta","year":"2022","journal-title":"International Journal of Applied and Basic Medical Research"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib23","article-title":"In vitro activity of WCK 771, a benzoquinolizine fluoroquinolone (levonadifloxacin) when tested against contemporary gram-positive and -negative bacteria from a global surveillance program","volume":"456","author":"Flamm","year":"2016","journal-title":"American Society for Microbiology General Meeting (MICROBE), Sunday"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib24","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/jac\/dkz493","article-title":"In vitro activity of a novel antibacterial agent, levonadifloxacin, against clinical isolates collected in a prospective, multicentre surveillance study in India during 2016-18","volume":"75","author":"Appalaraju","year":"2020","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib25","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1128\/AAC.01150-08","article-title":"In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types","volume":"53","author":"Bhagwat","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1469-0691.2004.01017.x","article-title":"Activity of the new quinolone WCK 771 against pneumococci","volume":"11","author":"Appelbaum","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib27","first-page":"e01048","article-title":"In Vitro Activity of Levonadifloxacin (WCK 771) against Chlamydia pneumoniae","volume":"63","author":"Kohlhoff","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib28","doi-asserted-by":"crossref","first-page":"e01348","DOI":"10.1128\/AAC.01348-18","article-title":"In Vitro Activities of the Benzoquinolizine Fluoroquinolone Levonadifloxacin (WCK 771) and Other Antimicrobial Agents against Mycoplasmas and Ureaplasmas in Humans, Including Isolates with Defined Resistance Mechanisms","volume":"62","author":"Xue","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib29","article-title":"In vitro activity of levonadifloxacin against legionella pneumophilia,","volume":"abstract P0620","author":"Dubois","year":"2018","journal-title":"European Congress of Clinical Microbiology and Infectious Disease (ECCMID)"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib30","article-title":"In vitro activity of WCK771, a broad-spectrum anti-MRSA benzoquinolizine subclass of quinolone against five biodefense bacterial pathogens.","volume":"Poster no- F1188","author":"Heine","year":"2015","journal-title":"ICAAC,"},{"key":"10.1016\/j.ijmmb.2022.11.005_bib31","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1128\/AAC.48.8.3188-3192.2004","article-title":"Antianaerobic Activity of a Novel Fluoroquinolone, WCK 771, Compared to those of Nine Other Agents","volume":"48","author":"Peric","year":"2004","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Indian Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S025508572200247X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S025508572200247X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T19:20:05Z","timestamp":1759346405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S025508572200247X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":31,"alternative-id":["S025508572200247X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijmmb.2022.11.005","relation":{},"ISSN":["0255-0857"],"issn-type":[{"value":"0255-0857","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"India-discovered levonadifloxacin & alalevonadifloxacin: A review on susceptibility testing methods, CLSI quality control and breakpoints along with a brief account of their emerging therapeutic profile as a novel standard-of-care","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Medical Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijmmb.2022.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Indian Association of Medical Microbiologists. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}